Skip directly to content


Xalkori® is a FDA-approved targeted therapy targeting lung cells harboring ALK or ROS-1 mutation1. Xalkori® has been enlisted as subsidized medical treatment against one specific disease by the Samaritan Fund. 2



  1. Xalkori® (crizotinib) Prescribing Information. Pfizer Corporation Hong Kong Limited: Version (August 2018)
  2. Information for Samaritan Fund & Community Care Fund Medical Assistance Programmes – Application for Drug Items. Hong Kong Hospital Authority. Accessed on 17 June 2019. Available at
[PP-CPF-HKG-0070] SEP 2019

Therapeutic Area Sub Category: